And that is before you account for the other psychoactive compounds present in whole psilocybin medicine. These compounds engage receptor pathways beyond the primary serotonergic mechanism, and they influence how a session unfolds and what a patient is able to access in the days and weeks that follow. Total Psilocin does not capture any of that. It is one data point in a much richer picture.

This is why Psylutions doses and documents by Total Psychedelic Potency. The full compound profile, and how it interacts across relevant receptor pathways, is where the clinical information actually lives. Every product we produce carries a Certificate of Analysis documenting that profile by batch, traceable from cultivation to administration. That documentation is not about compliance. It exists so facilitators can make defensible clinical decisions, and so that outcome data means something when we study it.

The Conversation the Field Keeps Avoiding

Here is where I want to be direct, because this is the part of the discussion the industry tends to sidestep.

CPTSD and depression are not the same diagnosis. Everyone knows that. What gets glossed over is that patients within the same diagnostic category are not equivalent either. Someone who developed CPTSD through childhood neglect and someone carrying the same diagnostic label after years of domestic violence are not interchangeable in a clinical setting. Someone sitting with fresh grief after an unexpected loss is in a fundamentally different physiological and psychological state than someone whose nervous system has lived in a pattern of chronic dysregulation for two decades. All of these patients may be appropriate candidates for psilocybin medicine. But the medicine selection, the dose, and the session structure that serve one of them well may be the wrong call for another.

This is what we mean when we talk about protocols matched to patient populations, and it is why a single standard product at a single standard dose falls short. What we call a Pharmacological Signature is the documented relationship between a product’s compound profile, the receptor pathways it engages, and what we observe clinically when that product is administered to particular patient populations in structured settings. Two products with identical Total Psilocin measurements can land very differently in the same population. Two populations with different diagnostic profiles are frequently better served by different products, even at equivalent doses. That level of specificity is what precision manufacturing makes possible. Undocumented, unverified medicine makes it impossible.

The Whole Fruit Problem

Let me be plain about this, because it gets argued constantly: whole fruiting bodies cannot be accurately dosed. A single mushroom is not a unit of medicine. Potency varies between individual fruits, between flushes from the same substrate, across harvest windows, and with growing conditions. None of that can be controlled at the point of administration. When a patient receives a weighed portion of whole fruit, what they are actually receiving is an approximation.

For a general wellness session where little is riding on the outcome, perhaps an approximation is acceptable. For someone whose depression has resisted twelve years of interventions, sitting down for the most significant clinical appointment of their adult life, it is not.